title: Inhalational botulism in rhesus macaques exposed to botulinum neurotoxin complex serotypes A1 and B1.
abstract: A recombinant botulinum vaccine (rBV A/B) is being developed for protection against inhalational intoxication with botulinum neurotoxin (BoNT) complex serotype A, subtype A1 (BoNT/A1), and BoNT serotype B, subtype B1 (BoNT/B1). A critical component for evaluating rBV A/B efficacy will be the use of animal models in which the pathophysiology and dose-response relationships following aerosol exposure to well-characterized BoNT are thoroughly understood and documented. This study was designed to estimate inhaled 50% lethal doses (LD(50)) and to estimate 50% lethal exposure concentrations relative to time (LCt(50)) in rhesus macaques exposed to well-characterized BoNT/A1 and BoNT/B1. During the course of this study, clinical observations, body weights, clinical hematology results, clinical chemistry results, circulating neurotoxin levels, and telemetric parameters were documented to aid in the understanding of disease progression. The inhaled LD(50) and LCt(50) for BoNT/A1 and BoNT/B1 in rhesus macaques were determined using well-characterized challenge material. Clinical observations were consistent with the recognized pattern of botulism disease progression. A dose response was demonstrated with regard to the onset of these clinical signs for both BoNT/A1 and BoNT/B1. Dose-related changes in physiologic parameters measured by telemetry were also observed. In contrast, notable changes in body weight, hematology, and clinical chemistry parameters were not observed. Circulating levels of BoNT/B1 were detected in animals exposed to the highest levels of BoNT/B1; however, BoNT/A1 was not detected in the circulation at any aerosol exposure level. The rhesus macaque aerosol challenge model will be used for future evaluations of rBV A/B efficacy against inhalational BoNT/A1 and BoNT/B1 intoxication.
authors.affiliation: Battelle Biomedical Research Center, West Jefferson, Ohio, USA.
authors.forename: Daniel C
authors.initials: DC
authors.lastname: Sanford
authors.forename: Roy E
authors.initials: RE
authors.lastname: Barnewall
authors.forename: Michelle L
authors.initials: ML
authors.lastname: Vassar
authors.forename: Nancy
authors.initials: N
authors.lastname: Niemuth
authors.forename: Karen
authors.initials: K
authors.lastname: Metcalfe
authors.forename: Robert V
authors.initials: RV
authors.lastname: House
authors.forename: Ian
authors.initials: I
authors.lastname: Henderson
authors.forename: Jeffry D
authors.initials: JD
authors.lastname: Shearer
mesh_terms: D000336:Aerosols; D000818:Animals; D001774:Blood Chemical Analysis; D001835:Body Weight; D001905:Botulinum Toxins / Q000633:toxicity*; D019274:Botulinum Toxins, Type A / Q000633:toxicity*; D001906:Botulism / Q000473:pathology* / Q000503:physiopathology*; D004195:Disease Models, Animal; D005260:Female; D007928:Lethal Dose 50; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D016019:Survival Analysis
chemical_list: D000336:Aerosols; C096323:rimabotulinumtoxinB; D001905:Botulinum Toxins; D019274:Botulinum Toxins, Type A